Three-quarters of patients in RA remission flare within 3 years of TNF inhibitor taper

Approximately 75% of patients in rheumatoid arthritis remission who taper TNF inhibitors to withdrawal experience a flare within 3 years, according to a study presented at ACR Convergence 2023. Just 15% of patients in RA remission who remained on stable TNF inhibition demonstrated flare during the same time period. The randomized, multicenter study found that only 25% of patients who tapered off TNF inhibitors remained flare-free after 3 years, compared to 85% of patients who remained on stable treatment. These results have important implications for clinical decision making, suggesting that the practice of tapering TNF inhibitor treatment should not be supported in this particular patient group.

Source link